Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots

Hasan Korkaya, Suling Liu, Max S. Wicha

Research output: Contribution to journalReview article

170 Citations (Scopus)

Abstract

There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents. By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit.

Original languageEnglish (US)
Pages (from-to)6125-6128
Number of pages4
JournalClinical Cancer Research
Volume17
Issue number19
DOIs
StatePublished - Oct 1 2011

Fingerprint

Neoplastic Stem Cells
Tumor Microenvironment
Cytokines
Stem Cells
Inflammation
Neoplasms
Cytokine Receptors
Stromal Cells
Interleukin-8
Interleukin-1
Wound Healing
Interleukin-6
Anti-Inflammatory Agents
Clinical Trials
Neoplasm Metastasis
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Regulation of cancer stem cells by cytokine networks : Attacking cancer's inflammatory roots. / Korkaya, Hasan; Liu, Suling; Wicha, Max S.

In: Clinical Cancer Research, Vol. 17, No. 19, 01.10.2011, p. 6125-6128.

Research output: Contribution to journalReview article

@article{c1a2680679f54f649f797af1bad2d644,
title = "Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots",
abstract = "There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents. By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit.",
author = "Hasan Korkaya and Suling Liu and Wicha, {Max S.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2743",
language = "English (US)",
volume = "17",
pages = "6125--6128",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Regulation of cancer stem cells by cytokine networks

T2 - Attacking cancer's inflammatory roots

AU - Korkaya, Hasan

AU - Liu, Suling

AU - Wicha, Max S.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents. By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit.

AB - There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents. By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=80053531658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053531658&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2743

DO - 10.1158/1078-0432.CCR-10-2743

M3 - Review article

C2 - 21685479

AN - SCOPUS:80053531658

VL - 17

SP - 6125

EP - 6128

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -